CD19 Research Products
CD19, a cell surface protein specific to B cells, has emerged as an effective immunotherapy target to treat B cell malignancies and autoimmune diseases.
By leveraging monoclonal antibodies, chimeric antigen receptor (CAR) T cells and NK cells, or bispecific T cell/NK cell engagers (BiTEs/BiKEs), CD19-directed immunotherapies aim to selectively eliminate CD19-expressing cells. In cancer, these ther...
Bispecific Antibodies & BiTE® (Bispecific T-Cell Engager) Services
CD3/CD19 BiTE® - Mechanism of Action
The CD3/CD19 BiTE® is a biopharmaceutical drug known as a Bi-specific T-cell engager for a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It binds to CD19 on cancer cells (e.g. Raji cells) and CD3 on T cells simultaneously, thus bringing T lymphocytes closer to cancer cells expressing specific cancer ...
CAR T-Cell Therapy
Overview
CAR-T is a cross of immunotherapy, gene therapy, and cellular therapy. Many successful immunotherapies are based on checkpoint inhibitors that block the mechanisms tumor cells use to hide from T cells. CAR-T immunotherapies go one step further by engineering T cells to enhance the immune response against a specific tumor antigen. CAR-T is a promising approach for cancer and other diseases, especially severe cancers that do not respond well to othe...
CAR-T Cell Therapy
Engineering T cells using a chimeric antigen receptor (CAR) to boost specific immune cell killing has made significant progress in the treatment of some cancer types. CAR-T cell therapy may also have potential benefits beyond cancer treatment, including treatments for infectious and chronic inflammatory diseases such as hepatitis, HIV/AIDS, lupus, and arthritis. Companies are also investigating CAR-T cell therapy in organ transplantation to eliminate the n...
CAR-T Cell Therapy
Engineering T cells using a chimeric antigen receptor (CAR) to boost specific immune cell killing has made significant progress in the treatment of some cancer types. CAR-T cell therapy may also have potential benefits beyond cancer treatment, including treatments for infectious and chronic inflammatory diseases such as hepatitis, HIV/AIDS, lupus, and arthritis. Companies are also investigating CAR-T cell therapy in organ transplantation to eliminate the n...
ADC and Antibody-Based Cancer Therapies
Antibody-based therapies, such as antibody-drug conjugates (ADCs) and multi-specific T cell engager molecules, provide a targeted approach to treating cancers.
Antibody-based therapies, such as antibody-drug conjugates (ADCs) and multi-specific T cell engager molecules, provide a targeted approach to treating cancers.
Monoclonal antibodies, which are laboratory-produced molecules that bind to a specif...
Citations
This page contains a list of scientific journal articles that have cited BPS products and services since 2013. We would like to congratulate all our loyal customers on their contributions to the scientific community. Our customers are truly amazing and dedicated scientists and this is evidenced by the outstanding research they are doing.
Search By Product Name or Catalog Number
Name
Title
10X HAT Assay Buffer (50095...
